Clinical Trial Update: The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating a radionuclide-labeled HER2-targeting antibody for diagnostic use in HER2-positive cancers, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Urothelial Carcinoma

Drugs mentioned

• Radionuclide-labeled HER2-targeting antibody (investigational) (HER2-targeting antibody labeled with radionuclide)

Snippet

Sponsor: Affiliated Hospital of Jiangnan University | Conditions: Breast Cancer, Gastric Cancer (GC) | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION